Five Prime Therapeutics 2Q16 Earnings Update August 2016

Five Prime Therapeutics' second quarter 2016 earnings presentation dated August 4, 2016. The biotech company presents its oncology-focused pipeline including clinical candidates Cabiralizumab (FPA008), FPA144, and FP-1039 across multiple tumor indications.